tqb3823
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT05021367)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05405439 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05021367 | Phase 1 | Sep 30, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1